Life Sciences M&A

A life sciences acquisition rests on one link: from the scientific evidence to the cash a product could earn. A compelling mechanism, a positive trial, a regulatory milestone, and a patent estate each answer a different question. The buyer has to establish what works, for which patients, under what development and manufacturing plan, and how the product will get paid for.

For CorpDev, the hard part is coordinating many specialists without losing sight of the investment decision. Scientific, clinical, regulatory, quality, manufacturing, intellectual property, market access, and commercial conclusions should all meet in one product profile and one development plan.

Pin down the asset and the rights you are buying

First decide what kind of asset it is: a marketed product, a development-stage drug, a discovery platform, a medical device, a services business, or a manufacturing capability. Then list the rights: indications, territories, fields of use, licenses, royalty obligations, supply rights, and any interests the seller keeps. Buying a company can also mean inheriting obligations to licensors or partners that limit future choices.

Write a target product profile: the intended patient or user, the clinical benefit, how the product differs, what delivering it requires, the development evidence, and the commercial assumptions. Use it as the shared reference for the valuation. If clinical leaders expect a narrow patient population while the commercial model assumes broad use, settle that conflict before approval.

Ask for the evidence that decides the next step

The table shows what to request for each question, and how a weak answer changes the investment.

Distinguish a topline results announcement from a complete study report; the valuation should rest on the second. Keep a register of open questions. For each significant gap, record which decision it affects, what evidence could resolve it, when that evidence will exist, and whether you are willing to own the uncertainty.

Compare the trial registry with the data room

Most sponsors register their clinical trials publicly, and US law requires registration for many of them. ClinicalTrials.gov keeps every version of a record, so its history of changes shows when a sponsor edited the primary outcome, planned enrollment, recruitment status, or completion dates. A terminated study also carries a short explanation of why it stopped. The EU's Clinical Trials Information System and the WHO registry portal cover studies registered elsewhere.

The data room holds the current protocol and the company's account of the program. Many differences between the two sources are innocent, such as late updates or corrected entries. Others matter: an endpoint changed after enrollment began, a completion date that has slipped three times, or a study the registry calls terminated and the presentation calls paused. Each of those needs an explanation, and the explanation can go to the heart of the value.

A hypothetical example:

Each row goes into the register of open questions with the decision it affects. Endpoint and enrollment changes go to biostatistics and regulatory affairs before anyone sets probabilities in the valuation. The same document-by-question method extends to rights, milestones, and budgets across programs. The one check that matters: treat each registry change as a question until the dated protocol amendment and the regulator correspondence explain it, because registry records are often updated late.

Keep development milestones separate from commercial success

For US drugs, the FDA describes a process that runs from discovery and preclinical research through clinical research and FDA review to post-market safety monitoring. Plan around the asset's actual stage and the work that remains. A positive study is one step, not the end of development. FDA drug development process.

Medical devices need their own analysis. FDA marketing pathways include 510(k) clearance, De Novo classification, and premarket approval, among others, and the right route depends on the device and the controls that apply. Have regulatory specialists confirm the route for the exact product and any planned changes. Calling every device milestone an “approval” misleads the committee. FDA device study and marketing guidance.

Keep commercial diligence as its own workstream. Model the eligible population, how patients are diagnosed or referred, adoption, treatment duration or device use, distribution, gross-to-net deductions such as rebates and discounts, and the competitive response. Test whether the product changes clinical practice enough to justify switching, and whether the organization can carry out the launch.

Value each development path and weight it by probability

Lay out the development paths explicitly. Each path specifies the evidence outcome, the decision that follows, the spending, launch timing, commercial profile, and the cash flows at the end of that path. Scientific and regulatory specialists should support each probability and explain both the reference class of comparable programs and the adjustments made for this asset. Never import a generic phase-success rate as if it described this program.

Risk-adjusted net present value (rNPV) is the probability-weighted present value of cash flows across those paths, less the relevant investment. Weight future development spending by the probability that the program reaches the stage where the money is spent. Spending committed whatever the outcome stays in every path.

Apply the discount rate consistently with the risk treatment. Counting the same development risk twice, once in the probabilities and again in an unexplained rate premium, understates the value. Finance should state the convention it chose and show the sensitivity. Include partner royalties, milestone payments, manufacturing investment, tax, working capital, and the limits on commercial exclusivity that counsel supports.

For a platform, value the identified programs explicitly, and separate evidence that the platform repeats from hope for future discoveries. Buying a discovery engine also means funding the people, assays, data, facilities, and governance that keep producing candidates.

Example: paying for evidence that does not exist yet

This case and its numbers are hypothetical.

A buyer evaluates a development asset. The seller's model assumes a broad patient population and a launch straight after the next planned study. Clinical review questions whether the study population supports that breadth. Manufacturing finds that more scale-up work is needed before supply is reliable.

The buyer builds four paths with specialist-supported assumptions, including the scale-up spending and the cost of holding the program together through a delay:

The broad-population path supplies about three-quarters of the value, and it rests on evidence the next study has yet to produce. A milestone-based structure may bridge the gap with the seller, but the milestone has to be an objectively verifiable event tied to economically meaningful rights. Pay for a regulatory event that leaves the commercial thesis open only if that choice is deliberate.

Choose a structure that fits the uncertainty

Compare an outright acquisition with licensing, co-development, an option to acquire, and staged ownership. Weigh control, funding commitments, termination rights, territory, governance, and the ability to integrate the scientific work. The structure with the lowest upfront cost can become expensive if it restricts development choices or creates conflicting incentives.

For contingent consideration, including milestone payments and the contingent value rights used in some public-company deals, define:

• The triggering event and how it is measured
• Payment timing and the dispute process
• Who is responsible for development, and what information the seller receives
• What happens if the program is discontinued or transferred

Counsel and accounting specialists should evaluate the actual instrument. A headline milestone value is worth less than the same amount of cash at closing.

Retain the scientific and operational knowledge needed for the next decision. Competitive pay matters, and so do program authority, research resources, credible leadership, and clarity on publication and development priorities. Map critical knowledge below the executive team, including assay development, manufacturing know-how, data management, and regulatory history.

Integrate without interrupting the program

Before closing, decide who owns trial operations, safety reporting, quality decisions, supply continuity, critical vendors, systems, and study records. Have functional leaders confirm the requirements and transition plans for the actual jurisdictions and products.

After closing, run a product-level dashboard: evidence milestones, enrollment or study progress where relevant, safety signals, manufacturing readiness, regulatory interactions, spending, supply, and launch preparation. Report changes to the product profile alongside changes to valuation assumptions. The program leader owns execution. Clinical, regulatory, and quality leaders keep their professional accountabilities. Finance reconciles the evolving investment case.

The committee needs an agreed product profile, an evidence assessment, a development and manufacturing plan, a rights map, a risk-adjusted valuation, and a funded downside plan. Together they make the uncertainty explicit enough to price and to govern.

Related resources

Continue with Earnouts, Business Case, and Due Diligence.